Jump to content
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
BIOPRO BW Logo

Main navigation

  • Start page Start page
  • About us

    About us

    Close Close
    • Team
      • Our authors
    • History and achievements
    • Supervisory Board
    • Career
    • Contact / Travel information
  • Activities

    Activities

    Close Close
    • Start-up support
    • Cooperation initiatives
    • Anlaufstelle Regulatorik Gesundheitswirtschaft BW
    • Internationalisation
  • Projects

    Projects

    Close Close
    • Current projects
      • Forum Health Region Baden-Württemberg
      • Alliance for sustainable medical technology
      • PRECISEU - PeRsonalised medicine Empowerment Connecting Innovation ecoSystems across EUrope
      • HACK-IT-NET - enabling an alpine region Health And Care Knowledge and Innovation Transfer NETwork
    • General Projects
      • LinkHealth@BW
    • Completed projects
      • MDR & IVDR Fast-Track Support BW
      • Photon-Counting (PC)-CT Consortium
      • Health Data Scenarios
      • Baden-Württemberg-Center for Academic Drug Discovery
      • Post-Brexit
      • MDR & IVDR Competence Centre BW (MIK)
      • The Phytopharmaceuticals and Valuable Plant Ingredients initiative
      • Advanced Imaging Utilization by Digital Data Application in Baden-Württemberg (PC3-AIDA)
  • Services

    Services

    Close Close
    • Funding
    • Research institutions
    • Healthcare industry database
    • Job market
    • Newsletter
    • Stay in touch with us!
  • Information

    Information

    Close Close
    • Press releases & contact
    • Publications
  • Events

    Events

    Close Close
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 12/05/2026

    The Silent Killer: Early Detection and Targeted Treatment of High Blood Pressure

    High blood pressure is one of the most common causes of heart attacks, strokes, kidney damage, and vascular diseases. Many people affected experience no symptoms for a long time. This is precisely why it is important to check your blood pressure regularly. To mark World Hypertension Day on May 17, the Medical Center – University of Freiburg is providing information on warning signs, diagnosis, and treatment options.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/silent-killer-early-detection-and-targeted-treatment-high-blood-pressure
  • Press release - 11/05/2026

    Radar warns of a risk of falling at the hospital

    The Medical Center – University of Freiburg has implemented a new system that helps nurses identify risky situations early on and provide more targeted assistance / Motion detection is performed using radar

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/radar-warns-risk-falling-hospital
  • Press release - 13/05/2026

    NVision Expands from Quantum Sensing to Quantum Computing to Accelerate Discovery and Validation of New Therapies

    NVision announced a $55 million Series B led by Abbott and unveiled PIQC, a new quantum computing platform built on its molecular quantum technology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nvision-expands-quantum-sensing-quantum-computing-accelerate-discovery-and-validation-new-therapies-en
  • Press release - 18/05/2026

    Gene scissors show promise for treating a rare immune disorder

    Medical Center – University of Freiburg demonstrates a fundamental therapeutic approach for hereditary immune system defects in a mouse model. The safety profile of genome editing varies significantly depending on the method and cell type.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gene-scissors-show-promise-treating-rare-immune-disorder
  • Press release - 15/05/2026

    Heidelberg Collaborative Research Centre “Molecular Circuits of Heart Disease” secures second funding period

    The Collaborative Research Centre (CRC) 1550 “Molecular Circuits of Heart Disease” at Heidelberg University is entering its second funding period. The German Research Foundation (DFG) has approved approximately EUR 17.4 million in funding for the next four years. The spokesperson is Johannes Backs, Professor of Experimental Cardiology at the Heidelberg Faculty of Medicine.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-collaborative-research-centre-molecular-circuits-heart-disease-secures-second-funding-period
  • Funding

    Funke Quantum-Driven Intelligence

    Funding programme, Funded by: SPRIN-D, sb_search.searchresult.label.programSubmissionDate: 06/09/2026
    https://www.gesundheitsindustrie-bw.de/en/database/funding/funke-quantum-driven-intelligence
  • Funding

    Funke QuantumSense Exploration

    Funding programme, Funded by: SPRIN-D, sb_search.searchresult.label.programSubmissionDate: 06/09/2026
    https://www.gesundheitsindustrie-bw.de/en/database/funding/funke-quantumsense-exploration
  • Funding

    Funke Quantum-Driven Intelligence

    Funding programme, Funded by: SPRIN-D, sb_search.searchresult.label.programSubmissionDate: 06/09/2026
    https://www.bio-pro.de/en/service/funding/funke-quantum-driven-intelligence
  • Funding

    Funke QuantumSense Exploration

    Funding programme, Funded by: SPRIN-D, sb_search.searchresult.label.programSubmissionDate: 06/09/2026
    https://www.bio-pro.de/en/service/funding/funke-quantumsense-exploration
  • Event - 17/09/2026 - 18/09/2026

    Translational Protein Biomarker Workshop

    Reutlingen, Informationsveranstaltung
    https://www.gesundheitsindustrie-bw.de/en/event/translational-protein-biomarker-workshop
  • Press release - 15/05/2026

    Neuroendocrine Tumors: Freiburg Becomes a European Center of Excellence

    The Medical Center – University of Freiburg has been certified for the first time as a “Center of Excellence” by the European Neuroendocrine Tumor Society (ENETS). The professional association recognizes specialized centers that treat rare tumor diseases in accordance with established quality standards. Neuroendocrine tumors are rare cancers that can arise from hormone-producing cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neuroendocrine-tumors-freiburg-becomes-european-center-excellence
  • Funding

    Continuous Hormone Monitoring

    Funding programme, Funded by: SPRIN-D, sb_search.searchresult.label.programSubmissionDate: 26/06/2026
    https://www.gesundheitsindustrie-bw.de/en/database/funding/continuous-hormone-monitoring
  • Funding

    Continuous Hormone Monitoring

    Funding programme, Funded by: SPRIN-D, sb_search.searchresult.label.programSubmissionDate: 26/06/2026
    https://www.bio-pro.de/en/service/funding/continuous-hormone-monitoring
  • Press release - 18/05/2026

    Unlocking the Lung’s Ability to Heal: NK Cell Immunotherapy offers New Hope for Fibrosis

    Research jointly led by scientists at the Heidelberg site of the German Center for Lung Research and investigators in Boston at Massachusetts General Hospital and Harvard Medical School identifies a new immunotherapy-based approach for lung fibrosis: reactivating natural killer cell (NK cells) to eliminate senescent fibroblasts, reverse scarring and restore the lung’s ability to heal.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/unlocking-lungs-ability-heal-nk-cell-immunotherapy-offers-new-hope-fibrosis
  • Press release - 21/05/2026

    Breakthrough in synthetic cell research

    Living systems such as cells rely on membrane pores and channels to transport molecules, exchange signals, and organize biochemical reactions. These functions emerge from dynamic interactions between molecular components. Researchers at the University of Stuttgart have used DNA nanotechnology to develop a synthetic membrane architecture that mimics such interactions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/breakthrough-synthetic-cell-research
  • Press release - 21/05/2026

    Why pain persists long after injuries have healed

    Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the mechanisms underlying chronic pain be translated into new therapeutic approaches? These questions have been at the core of Rohini Kuner’s research for many years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-pain-persists-long-after-injuries-have-healed
  • Press release - 28/05/2026

    An immune defence guide

    Which cellular processes ensure that immune responses are controlled precisely? A new study by the Institute of Cell Biology and Immunology Thurgau (BITG) and the University of Konstanz decodes a decisive signalling pathway.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-defence-guide
  • Press release - 21/05/2026

    Sartorius opens new competence center for cell and gene therapy components in Freiburg, Germany

    The life science group Sartorius has opened a new center in Freiburg, Germany, dedicated to the development and production of quality-critical materials for the cell and gene therapy market. In Freiburg, the company manufactures essential components such as cytokines and growth factors used in these novel therapies. With an investment of more than 140 million euros, Sartorius is reaffirming its strategic focus on this emerging business area.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sartorius-opens-new-competence-center-cell-and-gene-therapy-components-freiburg-germany
  • Press release - 29/05/2026

    FCI Supports Teaching Concept for the Chemistry of Tomorrow

    The German Chemical Industry Fund (FCI) is supporting the course offering ‘DigiChemJN’ at the Faculty of Chemistry and Pharmacy. DigiChemJN strengthens students’ data literacy by providing them qualifications in data-based research methods, experimental datasets, and artificial intelligence (AI).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fci-supports-teaching-concept-chemistry-tomorrow
  • Press release - 27/05/2026

    New Emmy Noether Junior Research group investigates the mode of action of Antimetabolite Chemotherapy

    How do antimetabolite cancer drugs damage the genetic material of malignantly transformed cells and thereby destroy them? How might these drugs be used more precisely, particularly in the treatment of pediatric tumors? A new research group led by Dr. Christopher Carnie, a scientist at the Heidelberg Faculty of Medicine at Heidelberg University, will address these questions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-investigates-mode-action-antimetabolite-chemotherapy
  • Press release - 26/05/2026

    Heidelberg based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide)

    Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now reached the world’s most important pharmaceutical market.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-based-development-revolutionizes-hepatitis-d-therapy-worldwide-us-food-and-drug-administration-fda-approves-hepatitis
  • Press release - 26/05/2026

    How blood stem cells diversify

    Different types of bone marrow stem cells give rise to blood and immune cells. A team led by Simon Haas now reports in ​“Nature Cell Biology” how that diversity develops. The findings could help improve stem cell therapies, including treatments for blood cancers.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-blood-stem-cells-diversify
  • Press release - 27/05/2026

    Funding for three Collaborative Research Centres at DZHK sites

    The German Research Foundation (DFG) is establishing new Collaborative Research Centres and extending existing research networks. Several DZHK sites are also involved. Particular emphasis is being placed on new research approaches to inflammation and thrombosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/Funding-for-three-Collaborative-Research-Centres-at-DZHK-sites
  • Press release - 01/06/2026

    Central Institute of Mental Health joins international Lancet Commission on schizophrenia

    Leading scientists are pooling their expertise to further advance research and care for psychotic disorders and to align them more closely with the needs of affected individuals.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/central-institute-mental-health-joins-international-lancet-commission-schizophrenia
  • Press release - 03/06/2026

    Fat hack protects against cell death

    In response to stress or damage, cells undergo senescence and stop dividing. However, if senescent cells accumulate in tissues over the long term, chronic inflammation occurs and the risk of cancer increases. Researchers at the German Cancer Research Center (DKFZ) have now discovered a previously unknown mechanism by which senescent cells protect themselves from oxidative stress and a specific form of cell death known as ferroptosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fat-hack-protects-against-cell-death
  • Press release - 03/06/2026

    Potential Biomarker for personalized Leukemia therapy identified

    Researchers at Heidelberg Faculty of Medicine at Heidelberg University, in collaboration with partners from 29 German study centers, have found evidence of a potential biomarker for personalized therapy of acute myeloid leukemia (AML) in a Phase II study. Analyses showed that certain patients could benefit from additional treatment with the drug Motixafortide in addition to standard chemotherapy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/potential-biomarker-personalized-leukemia-therapy-identified
  • Quantum sensors for magnetic measurements - 02/06/2026 Graphical representation of a skin-coloured muscle fibre bundle with muscle fibres. Around a protruding muscle fibre and its muscle cells, black circles are shown.

    New insights into muscle physiology – contactless and three-dimensional

    Contactless measurement of muscle activity and training effects: using highly sensitive quantum sensors, researchers at the Universities of Tübingen and Stuttgart are setting new standards. This technology has the potential to revolutionise clinical diagnostics and optimise training and neuroscience research.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-insights-muscle-physiology-contactless-and-three-dimensional
  • Alliance for Sustainable Medical Technology - 26/06/2026 Logo Allianz für nachhaltige Medizintechnik

    Redesigning for Reuse and Re-X - systematically redesigning products for the circular economy and reuse

    online, Webinar
    https://www.gesundheitsindustrie-bw.de/en/event/redesigning-reuse-and-re-x-systematically-redesigning-products-circular-economy-and-reuse
  • Press release - 02/06/2026

    New approach to prevent treatment-induced leukemia Protective mechanism against DNA damage caused by chemotherapy and radiotherapy discovered

    In rare cases, cancer treatments can cause serious long-term effects. These include so-called secondary leukemias. This form of blood cancer can develop when chemotherapy or radiotherapy damages the genetic material of healthy cells. A research team led by a scientist from Ulm has now discovered a molecular protective mechanism against such genomic damage: a peptide.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-prevent-treatment-induced-leukemia-protective-mechanism-against-dna-damage-caused-chemotherapy-and-radiotherapy-dis
  • Press release - 01/06/2026

    Excellent Doctoral Training Enters Second Funding Phase: Medical Faculties at Heidelberg University Continue Successful Graduate Program in the field of Immunology

    The German Research Foundation (DFG) funds continuation of Research Training Group (RTG) 2727 “Checkpoints of Innate Immunity in Cancer and Tissue Damage”, with around €5,8 million.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/excellent-doctoral-training-enters-second-funding-phase-medical-faculties-heidelberg-university-continue-successful-graduate-pro
  • Find the specialist you are looking for

    Team

    https://www.bio-pro.de/en/biopro/team
  • Press release - 10/06/2026

    AI Diagnoses Brain Tumors in Minutes Instead of Weeks

    Experts in Heidelberg have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes, and could accelerate the diagnosis of brain tumors worldwide.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-diagnoses-brain-tumors-minutes-instead-weeks
  • Press release - 10/06/2026

    NEURA Robotics announces record series C of up to $1,4 Billion to accelerate the world's leading physical AI Platform

    NEURA Robotics (“NEURA”), the pioneer in cognitive robotics and creator of the Neuraverse, today announced a landmark Series C financing with a total round size of up to $1.4 billion to accelerate its mission of building the world’s leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastructure.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neura-robotics-announces-record-series-c-1-dollars-4-cents-billion-accelerate-worlds-leading-physical-ai-platform
  • Press release - 01/06/2026

    More precise therapeutic agents for neuropsychiatry: The NMI is helping to unravel complex receptor mechanisms

    How can effective treatments for neuropsychiatric disorders be developed without having to accept unwanted side effects? Researchers at the NMI have made an important contribution to this field. In their recent paper, “NMDA receptor subtype differential affinity as a key enabler for precision neuropsychiatry,” they demonstrate how specifically targeting subunits of the NMDA receptor opens up new avenues for safer medications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/more-precise-therapeutic-agents-neuropsychiatry-nmi-helping-unravel-complex-receptor-mechanisms
  • Press release - 12/06/2026

    The Heidelberg and Mannheim University Hospitals consortium has taken first place in the Stern hospital rankings

    For the first time in 14 years, there has been a change at the top of the hospital rankings, which are published annually by the MINQ Institute in collaboration with Stern. In its very first year of existence, the Heidelberg and Mannheim University Hospitals Consortium has taken first place.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-and-mannheim-university-hospitals-consortium-has-taken-first-place-stern-hospital-rankings
  • Funding

    Wittenstein Biointelligence Award

    Competition, Funded by: Wittenstein Foundation, sb_search.searchresult.label.programSubmissionDate: 31/07/2026
    https://www.gesundheitsindustrie-bw.de/en/database/funding/wittenstein-biointelligence-award-en
  • Funding

    Wittenstein Biointelligence Award

    Competition, Funded by: Wittenstein Foundation, sb_search.searchresult.label.programSubmissionDate: 31/07/2026
    https://www.bio-pro.de/en/service/funding/wittenstein-biointelligence-award-en
  • Press release - 12/06/2026

    The University of Freiburg and Nagoya University agree on a joint doctoral programme

    The University of Freiburg and Nagoya University are strengthening their strategic partnership through a joint doctoral programme and the Nagoya University Global Campus, which serves as a permanently staffed representative office in Freiburg.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/university-freiburg-and-nagoya-university-agree-joint-doctoral-programme
  • Press release - 10/06/2026

    Can Aztekin receives 2026 Schering Young Investigator Award

    This year’s Schering Young Investigator Award has been awarded to Can Aztekin, a Max-Planck-Research Group Leader at the Friedrich Miescher Laboratory of the Max Planck Society in Tübingen, to recognize his significant work in the field of regenerative biology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/can-aztekin-receives-2026-schering-young-investigator-award
  • Press release - 16/06/2026

    Kickoff for the EU-Pathfinder Project HEARTCORE at the NMI

    It goes without saying that new drug compounds should place as little strain on the heart as possible. But how can potential effects be reliably predicted? Researchers from the NMI, Hannover Medical School (project lead), the Universitat Politecnica de Valencia, and industry partners Multi Channel Systems and Foresee Biosystems are tackling this challenge in the new HEARTCORE project.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/kickoff-eu-pathfinder-project-heartcore-nmi
  • Press release - 11/06/2026

    VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026

    VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, today announced that its previously announced business combination (“Business Combination”) with Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, was closed successfully (the “Closing”)

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/veraxa-biotech-debut-publicly-traded-company-pioneering-next-generation-cancer-therapies-june-11-2026
  • Event - 21/10/2026 - 22/10/2026 D4F_LinkedIn.png

    Diagnostics-4-Future Conference 2026

    Konstanz, Germany , Kongress/Symposium
    https://www.gesundheitsindustrie-bw.de/en/event/diagnostics-4-future-conference-2026
  • Press release - 18/06/2026

    Tailor-made functionalized gelatin – manufactured with reproducible results

    Gelatin is a versatile natural material. To tailor its properties specifically to the various applications in medicine, diagnostics, and cosmetics, the Fraunhofer IGB has developed a toolbox for chemical functionalization. With the help of automated processes, the modifications can now be scaled under defined conditions, and reproducible batches of modified gelatin can be produced on a scale ranging from grams to kg for customer sampling.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tailor-made-functionalized-gelatin-manufactured-reproducible-results
  • Press release - 19/06/2026

    Universität Heidelberg: Humboldt professorship for leading international researcher

    In order to further strengthen Heidelberg University as an internationally recognized location of infection research, Prof. Dr Mathias Lichterfeld has been selected for an Alexander von Humboldt Professorship endowed with 7.8 million euros. Leading international academics are granted this most valuable of German research awards to enable them to conduct long-term, cutting-edge research at German universities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/universitaet-heidelberg-humboldt-professorship-leading-international-researcher
  • Funding

    4C Accelerator

    Funding programme, Funded by: Baden-Württemberg Ministry of Economics, Labor and Tourism and its Startup BW campaign, the B. Braun Stiftung, and the Hector Stiftung, sb_search.searchresult.label.programSubmissionDate: 03/08/2026
    https://www.gesundheitsindustrie-bw.de/en/database/funding/4c-accelerator
  • Funding

    4C Accelerator

    Funding programme, Funded by: Baden-Württemberg Ministry of Economics, Labor and Tourism and its Startup BW campaign, the B. Braun Stiftung, and the Hector Stiftung, sb_search.searchresult.label.programSubmissionDate: 03/08/2026
    https://www.bio-pro.de/en/service/funding/4c-accelerator
  • Press release - 19/06/2026

    QS World University Rankings 2027: The University of Freiburg ranks among the top 10 nationally across several indicators

    In the latest QS World University Rankings, the University of Freiburg is ranked 14th nationally. It is among the top ten German universities in three indicators. In the overall international ranking, it is ranked 245th out of more than 1,500 other universities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/qs-world-university-rankings-2027-university-freiburg-ranks-among-top-10-nationally-across-several-indicators
  • Press release - 22/06/2026

    A new look at how the heart really beats

    Medical Center – University of Freiburg has created a new miniature animation of the beating heart. To the knowledge of Medical Center – University of Freiburg, it is the first schematic 3D animation to showcase the dynamic movement of the heart in an anatomically and temporally representative manner. It shows that the heart pushes blood into the body while simultaneously drawing blood in from the veins.

    https://www.gesundheitsindustrie-bw.de/en/article/new-look-how-heart-really-beats
  • Press release - 18/06/2026

    Medical Diagnostics and Materials Analysis Using Compact Magnetic Resonance

    The Collaborative Research Center (SFB) “High Performance Compact Magnetic Resonance” (HyPERiON) has been exploring new avenues in magnetic resonance technology since 2022. Under the leadership of the Karlsruhe Institute of Technology (KIT), the researchers aim to develop high-performance magnetic resonance systems in a benchtop format to make them suitable for widespread use.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/medical-diagnostics-and-materials-analysis-using-compact-magnetic-resonance
  • Funding

    Communicator Award 2027

    Competition, Funded by: DFG - German Research Foundation, sb_search.searchresult.label.programSubmissionDate: 30/09/2026
    https://www.bio-pro.de/en/service/funding/communicator-award-2027

Page 29 / 30

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • eine Seite zurück
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • About us
    • Team
    • History and achievements
    • Supervisory Board
    • Career
    • Contact / Travel information
  • Activities
    • Start-up support
    • Cooperation initiatives
    • Anlaufstelle Regulatorik Gesundheitswirtschaft BW
    • Internationalisation
  • Projects
    • Current projects
    • General Projects
    • Completed projects
  • Services
    • Funding
    • Research institutions
    • Healthcare industry database
    • Job market
    • Newsletter
    • Stay in touch with us!
  • Information
    • Press releases & contact
    • Publications
  • Events
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.bio-pro.de/en/search